Table 1 Clinical characteristics of the cohort (n = 200)

Age (years)

69.3 (SD 8.6)

69 (SD 8.8)

70 (SD 8.3)

Sex–Males (%)

134 (67%)

86 (67%)

48 (68%)

Smoking- current/non smokers (%)

65/40 (33/20)

44/24 (34/19)

21/16 (30/23)

BMI^a

27 (SD 3.9)

26 (SD 3.7)

28 (SD 3.9)***

Degree of stenosis (%)

90 (IQR 80-95)

90 (IQR 80-95)

90 (IQR 75-95)

Hypertension (%)

147 (74)

94 (73)

53 (75)

hsCRP (mg/L)^b

3.9 (IQR 2.0-6.6)

3.8 (IQR 2-6.7)

4.2 (IQR 1.9-6.6)

HbA1c (mmol/mol)^e

44 (IQR 38-56)

39 (IQR 36-41)

56 (IQR 47-66)***

Plasma lipoproteins (mmol/L)

 Total cholesterol

4.4 (SD 1.1)

4.6 (SD 1.1)

4.2 (SD 1.1)*

 LDL^c

2.5 (IQR 1.9-3.2)

2.6 (IQR 2.0-3.3)

2.2 (IQR 1.6-3.0)**

 HDL^d

1.1 (IQR 0.9-1.3)

1.1 (IQR 0.9-1.3)

1.0 (IQR 0.8-1.3)

 Triglycerides

1.3 (IQR 1.0-1.8)

1.2 (IQR 0.9-1.7)

1.6 (IQR 1.0-2.1)**

Blood glucose lowering treatment, n(%)

 Life style changes

11 (6%)

–

11 (15%)

 Oral glucose lowering treatment

37 (19%)

–

37 (52%)

 Insulin

22 (11%)

–

22 (31%)

 Insulin and oral glucose lowering

12 (6%)

–

12 (17%)

Blood pressure lowering treatment, n(%)

 RAAS inhibitor

101 (51%)

58 (45%)

43 (61%)*

 Beta blocker

98 (49%)

59 (46%)

39 (55%)

Statin treatment, n(%)

164 (82%)

100 (78%)

64 (90%)*